Pathogens and Immunity · 2024 · 46 citations · 12 references
PharmacyImmunologyInfectious DiseasesImmunotherapyMolecular VirologyMonoclonal AntibodiesAntibody CharacterizationAntibody DiscoveryMonoclonal Antibody TechnologyMonoclonal Antibody TherapyTherapeutic Antibody DevelopmentTherapeutic Monoclonal AntibodiesResistance-associated Viral VariantsSars-cov-2 Antiviral ResistanceSars-cov-2 Antiviral TherapySars-cov-2 Infection
Background: First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, 2 novel mAbs, VYD222/Pemivibart and AZD3152/Sipavibart, were approved by health authorities, but their activity against contemporary JN.1 sublineages is poorly characterized. Methods: We isolated authentic JN.1.1, KP.1.1, LB.1, and KP.3.3 viruses and evaluated their sensitivity to neutralization by these mAbs in 2 target cell lines. Results: Compared to ancestral strains, VYD222/Pemivibart remained moderately active against JN.1 subvariants, with a strong increase of 50% Inhibitory Concentration (IC50), reaching up to 3 to 15 µg/mL for KP3.3. AZD3152/Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP.1.1, LB.1, and KP3.3. Conclusions: Our results highlight the need for a close clinical monitoring of VYD222/Pemivibart and raise concerns about the clinical efficacy of AZD3152/Sipavibart.
12
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Delphine Planas, Nell Saunders, Piet Maes et al. · Nature · 2021 · 1.6K citations · Full text
Syncytia formation by SARS‐CoV‐2‐infected cells
Julian Buchrieser, Jérémy Dufloo, Mathieu Hubert et al. · The EMBO Journal · 2020 · 502 citations · Full text
Erratum To: Syncytia formation by SARS‐CoV‐2‐infected cells
Julian Buchrieser, Jérémy Dufloo, Mathieu Hubert et al. · The EMBO Journal · 2021 · 385 citations · Full text